12 active not recruiting, 5 completed, 5 recruiting. 22 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Active not recruiting 12, Completed 5, Recruiting 5 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow tremelimumab: new trials by email Literature Review of tremelimumab trials Research Report on tremelimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma Durvalumab Plus Tremelimumab, HAIC (GEMOX) - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | UNICANCER | 196 | 2025-11-14 | 2026-02-03 |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma Tremelimumab, Rilvegostomig, Bevacizumab - Hepatocellular Carcinoma | Phase 3 | Recruiting | AstraZeneca | 1220 | 2025-05-06 | 2026-10-13 |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab, Durvalumab - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 89 | 2024-01-11 | 2026-09-22 |
| Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 111 | 2023-06-27 | 2026-09-14 |
| Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC Durvalumab, Tremelimumab - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 214 | 2023-02-15 | 2026-06-26 |
| Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE) - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 760 | 2022-03-28 | 2026-10-16 |
| Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC Durvalumab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, NSCLC, Stage III | Phase 3 | Recruiting | Stanford University | 48 | 2021-08-25 | 2026-09-30 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 712 | 2021-08-05 | 2026-06-04 |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy Durvalumab, Tremelimumab, Placebo - Small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 730 | 2018-09-27 | 2025-11-21 |
| Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer Durvalumab, Tremelimumab, Cisplatin + Gemcitabine - Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1246 | 2018-09-27 | 2026-08-20 |
| Renal Adjuvant MultiPle Arm Randomised Trial Durvalumab, Tremelimumab - Renal Cell Carcinoma | Phase 3 | Recruiting | University College, London | 1750 | 2018-07-19 | 2020-09-07 |
| Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2) - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 1324 | 2017-10-11 | 2026-10-07 |
| An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab - Advanced Solid Malignancies | Phase 3 | Completed | AstraZeneca | 867 | 2017-06-05 | 2022-12-22 |
| Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). Durvalumab, Tremelimumab, Abraxane + carboplatin - Non Small Cell Lung Cancer NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 1186 | 2017-06-01 | 2026-03-13 |
| Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) Durvalumab, Tremelimumab, Carboplatin - Small Cell Lung Carcinoma Extensive Disease | Phase 3 | Active not recruiting | AstraZeneca | 987 | 2017-03-27 | 2026-07-16 |
| Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer MEDI4736 (Durvalumab), Tremelimumab, Cisplatin - Urothelial Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1126 | 2015-11-02 | 2026-07-14 |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer MEDI4736, Tremelimumab, MEDI4736+Tremelimumab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Completed | AstraZeneca | 823 | 2015-10-15 | 2021-10-13 |
| Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer MEDI4736, MEDI4736 + Tremelimumab, Standard of Care - Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | Phase 3 | Completed | AstraZeneca | 736 | 2015-09-09 | 2021-02-10 |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin - Non-Small-Cell Lung Carcinoma NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 1118 | 2015-07-21 | 2026-08-06 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Hepatocellular (7) · Carcinoma, Non-Small-Cell Lung (2) · Liver Neoplasms (2) · Small Cell Lung Carcinoma (2) · Urinary Bladder Neoplasms (2) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1)
AstraZeneca (17) · AbbVie (1) · NRG Oncology (1) · Stanford University (1) · UNICANCER (1) · University College, London (1)
United States (19) · Italy (16) · France (15) · Germany (15) · South Korea (15) · Spain (15) · Japan (14) · Taiwan (14) · Canada (13) · Poland (11) · Russia (11) · Brazil (10) · United Kingdom (10) · Vietnam (10) · China (9)
Haiyi Jiang, M.D. (2) · James Larkin (1) · Jennifer Y Wo (1) · Laure Monard (1) · Lorenza Rimassa, MD (1) · Maximilian Diehn, MD (1) · Naiyer Rizvi, MD (1) · Nassim Morsli, MD (1) · Paul Stockman, MBChB, PhD (1) · Richard Olsson (1) · Stephen Chan, MD (1) · Stuart McIntosh, MD (1) · Tanguy Seiwert (1)
PMID 23295794, PMID 30227886, PMID 31590988, PMID 31948903, PMID 32201234, PMID 32271377, PMID 32294530, PMID 32971005, PMID 33285097, PMID 33526329, PMID 33684371, PMID 33775558, PMID 34056687, PMID 34538401, PMID 34538402, PMID 35042068, PMID 36327426, PMID 37676259, PMID 37678916, PMID 37777827, PMID 38319892, PMID 38430375, PMID 38805668, PMID 38811992, PMID 39089633, PMID 39094286, PMID 39243945, PMID 39268857, PMID 40222621, PMID 40331625, PMID 40976711, PMID 41585428, PMID 41921748, PMID 42108643, PMID 42636832, PMID 42806195, PMID 42838226
2015 (2), 2016 (2), 2018 (2), 2023 (2), 2014 (1), 2017 (1), U10CA180868 (1)